Please login to the form below

Not currently logged in
Email:
Password:

SMA Europe

This page shows the latest SMA Europe news and features for those working in and with pharma, biotech and healthcare.

Novartis faces criticism over Zolgensma ‘health lottery’

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'. Novartis has responded to criticism over its managed access programme for spinal muscular atrophy (SMA) gene therapy Zolgensma, with patient groups accusing the company of ... For SMA Europe, the fact

Latest news

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    Biogen closed in on EU approval of its spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) in Europe, having already picked up a US approval for the highly-priced drug as 2016 ... Spinraza is the first drug for the rare and often fatal genetic

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics